View : 30 Download: 5

Effect of Immunotherapy on Seizure Outcome in Patients with Autoimmune Encephalitis: A Prospective Observational Registry Study

Title
Effect of Immunotherapy on Seizure Outcome in Patients with Autoimmune Encephalitis: A Prospective Observational Registry Study
Authors
Byun, Jung-IckLee, Soon-TaeJung, Keun-HwaSunwoo, Jun-SangMoon, JangsupLim, Jung-AhLee, Doo YoungShin, Yong-WonKim, Tae-JoonLee, Keon-JooLee, Woo-JinLee, Han-SangJun, JinsunKim, Dong-YubKim, Man-YoungKim, HyunjinKim, Hyeon JinSuh, Hong IlLee, YoojinKim, Dong WookJeong, Jin HoChoi, Woo ChanBae, Dae WoongShin, Jung-WonJeon, DaejongPark, Kyung-IlJung, Ki-YoungChu, KonLee, Sang Kun
Ewha Authors
문장섭
Issue Date
2016
Journal Title
PLOS ONE
ISSN
1932-6203JCR Link
Citation
vol. 11, no. 1
Publisher
PUBLIC LIBRARY SCIENCE
Indexed
SCIE; SCOPUS WOS scopus
Abstract
Objective To evaluate the seizure characteristics and outcome after immunotherapy in adult patients with autoimmune encephalitis (AE) and new-onset seizure. Methods Adult (age >= 18 years) patients with AE and new-onset seizure who underwent immunotherapy and were followed-up for at least 6 months were included. Seizure frequency was evaluated at 2-4 weeks and 6 months after the onset of the initial immunotherapy and was categorized as "seizure remission", "> 50% seizure reduction", or "no change" based on the degree of its decrease. Results Forty-one AE patients who presented with new-onset seizure were analysed. At 2-4 weeks after the initial immunotherapy, 51.2% of the patients were seizure free, and 24.4% had significant seizure reduction. At 6 months, seizure remission was observed in 73.2% of the patients, although four patients died during hospitalization. Rituximab was used as a second-line immunotherapy in 12 patients who continued to have seizures despite the initial immunotherapy, and additional seizure remission was achieved in 66.6% of them. In particular, those who exhibited partial response to the initial immunotherapy had a better seizure outcome after rituximab, with low adverse events. Conclusion AE frequently presented as seizure, but only 18.9% of the living patients suffered from seizure at 6 months after immunotherapy. Aggressive immunotherapy can improve seizure outcome in patients with AE.
DOI
10.1371/journal.pone.0146455
Appears in Collections:
연구기관 > 의과학연구소 > Journal papers
Files in This Item:
Effect of Immunotherapy on Seizure Outcome in Patients with Autoimmune Encephalitis.PDF(1.03 MB)Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE